Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Bioorg Med Chem Lett ; 28(7): 1198-1206, 2018 04 15.
Artículo en Inglés | MEDLINE | ID: mdl-29525219

RESUMEN

Gram-positive bacteria are among the most common human pathogens associated with clinical infections which range from mild skin infections to sepsis. Resistance towards existing class of drugs by Gram-positive bacteria including methicillin resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis (MRSE) and vancomycin resistant enterococci (VRE) is a growing concern. There is an urgent need to discover new antibiotics which are active against resistant strains of Gram positive bacteria. We report herein a novel class of spiropyrimidinetrione oxazolidinone derivatives as novel antibacterial agents. Key step towards the synthesis of title compounds involved the use of tert-amino reaction with [1,5]-hydride shift leading to the new CC bond formation. Compound 30n has demonstrated potent antibacterial activity against a panel of Gram-positive microbial strains including MRSA, MRSE, and LNZ and vancomycin resistant strains of E. faecalis. Further, molecular docking studies suggest that 30n has binding mode similar to that of LNZ in 50S RNA ribosome.


Asunto(s)
Antibacterianos/farmacología , Diseño de Fármacos , Oxazolidinonas/farmacología , Pirimidinonas/farmacología , Compuestos de Espiro/farmacología , Antibacterianos/síntesis química , Antibacterianos/química , Relación Dosis-Respuesta a Droga , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Simulación del Acoplamiento Molecular , Estructura Molecular , Oxazolidinonas/síntesis química , Oxazolidinonas/química , Pirimidinonas/síntesis química , Pirimidinonas/química , Compuestos de Espiro/síntesis química , Compuestos de Espiro/química , Staphylococcus epidermidis/efectos de los fármacos , Relación Estructura-Actividad , Enterococos Resistentes a la Vancomicina/efectos de los fármacos
2.
Bioorg Med Chem Lett ; 28(17): 2993-2997, 2018 09 15.
Artículo en Inglés | MEDLINE | ID: mdl-30017316

RESUMEN

FimH is a type I fimbrial lectin located at the tip of type-1 pili of Gram-negative uropathogenic Escherichia coli (UPEC) guiding its ability to adhere and infect urothelial cells. Accordingly, blocking FimH with small molecule inhibitor is considered as a promising new therapeutic alternative to treat urinary tract infections caused by UPEC. Herein, we report that compounds having the S-glycosidic bond (thiomannosides) had improved metabolic stability and plasma exposures when dosed orally. Especially compound 5h showed the potential to inhibit biofilm formation and also to disrupt the preformed biofilm. And compound 5h showed prophylactic effect in UTI model in mice.


Asunto(s)
Proteínas Fimbrias/antagonistas & inhibidores , Manósidos/farmacología , Infecciones Urinarias/tratamiento farmacológico , Adhesinas de Escherichia coli/metabolismo , Administración Oral , Animales , Biopelículas/efectos de los fármacos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Proteínas Fimbrias/metabolismo , Manósidos/administración & dosificación , Manósidos/química , Ratones , Simulación del Acoplamiento Molecular , Estructura Molecular , Relación Estructura-Actividad , Infecciones Urinarias/orina
3.
Bioorg Med Chem Lett ; 27(11): 2313-2318, 2017 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-28442252

RESUMEN

Designing drug candidates exhibiting polypharmacology is one of the strategies adopted by medicinal chemists to address multifactorial diseases. Metabolic disease is one such multifactorial disorder characterized by hyperglycaemia, hypertension and dyslipidaemia among others. In this paper we report a new class of molecular framework combining the pharmacophoric features of DPP4 inhibitors with those of ACE inhibitors to afford potent dual inhibitors of DPP4 and ACE.


Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Inhibidores de la Dipeptidil-Peptidasa IV/uso terapéutico , Síndrome Metabólico/tratamiento farmacológico , Inhibidores de la Enzima Convertidora de Angiotensina/química , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Animales , Inhibidores de la Dipeptidil-Peptidasa IV/química , Inhibidores de la Dipeptidil-Peptidasa IV/farmacología , Perros , Humanos , Concentración 50 Inhibidora , Ratones , Microsomas Hepáticos/efectos de los fármacos , Simulación del Acoplamiento Molecular , Ratas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA